Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura
The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the spreading cortical brain activity that causes or contributes to the migraine headache. Two TMS treatments at an intensity of <1 Tesla for ~500 microseconds, approximately 30 seconds apart, may stop the aura and prevent the subsequent headache.
In the Lead-in Phase participants will use a Personal Digital Assistant (PDA) to keep an electronic diary of their migraine episodes. During a migraine episode, as well as the time in between headaches, the PDA prompts the participant to answer questions. Each evening, the participant will place the PDA into an electronic telephone cradle, and the information will be transmitted electronically from the PDA to the data management team to assess the frequency of migraine episodes and participant proficiency with the PDA. During this one month period, the participant must experience at least one migraine with aura episode to enter the Treatment Phase.
After one month, the participant will return to the clinic with their PDA and will enter the Treatment Phase to be randomized to either the TMS only group or the Sham stimulation only group. Participant will enter information into the PDA for three migraine auras treated or three months, which ever comes first.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Active Transcranial Magnetic Stimulation (TMS) Device | Active Comparator | Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura. |
|
| Sham TMS Device | Sham Comparator | Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Active Transcranial Magnetic Stimulation (TMS) Device | Device | Transcranial Magnetic Stimulation Device treatment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Experiencing no Pain at Two Hours Post-treatment | Number of participants experiencing no pain at two hours post-treatment divided by total number of participants treated. For each treated aura episode during the migraine treatment phase, the subjects rated the pain intensity of their headache as none, mild, moderate or severe at baseline (before application of the study device) at 30 minutes, and at 1, 2, 24, and 48 hours posttreatement. | Two hours |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Have Symptoms of Nausea | Percentage of participants who have symptoms of nausea two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. |
Not provided
Inclusion Criteria:
18 - 65 years
Will comply with requirements of the protocol
Have a consistent history of migraine with visual aura of at least one year
•>30% of episodes have a visual aura preceding headaches
Approximately 90% of the time have moderate or severe headaches following their aura
Fulfills the International Classification of Headache Disorders, 2nd Edition(ICHD-II) criteria(for migraine headache with aura after administration of a clinical interview by study personnel
Has a history of 1-8 migraine headache episodes with aura per month
Can differentiate a migraine headache from other types of headaches
Participant is post-menopausal, sterilized, not breastfeeding, her pregnancy test is negative
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard B Lipton, MD | Albert Einstein College of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| San Francisco Headache Clinic | San Francisco | California | 94109 | United States | ||
| Mile High Research Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20206581 | Derived | Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010 Apr;9(4):373-80. doi: 10.1016/S1474-4422(10)70054-5. Epub 2010 Mar 4. |
Not provided
Not provided
267 participants enrolled in the 30 day Lead-In phase as described. 66 participants did not experience migraine in the 30 days allotted and therefore were not moved to the treatment phase. 201 participants were moved to the treatment phase
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 30 Day Lead in Phase | some particpants did not experience migrain in the 30 days allotted and therefore were not moved to the treatment phase |
| FG001 | Active TMS | Active Transcranial Magnetic Stimulation Device |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Pretreatment Phase |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sham TMS Device | Device | Simulated Sham treatment without TMS delivery |
|
| two hours post treatment |
| Percentage of Participants Who Have Symptoms Phonophobia | Percentage of participants who have symptoms of phonophobia two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. | 2 hours post treatment |
| Percentage of Participants Who Have Photophobia | Percentage of participants who have symptoms of photophobia two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. | 2 hours post treatment |
| Denver |
| Colorado |
| 80218 |
| United States |
| Diamond Headache Clinic, LTD | Chicago | Illinois | 60614 | United States |
| Michigan Head Pain & Neurological Institute | Ann Arbor | Michigan | 48104 | United States |
| Westside Family Medical Center | Kalamazoo | Michigan | 49009 | United States |
| Clinvest, Inc. | Springfield | Missouri | 65807 | United States |
| Mercy Health Research | St Louis | Missouri | 63141 | United States |
| Kirchner Headache Clinic | Omaha | Nebraska | 68144 | United States |
| Montefiore Headache Center | The Bronx | New York | 10461 | United States |
| The Ohio State University | Columbus | Ohio | 43210 | United States |
| Jefferson Headache Center | Philadelphia | Pennsylvania | 19107 | United States |
| Nashville Neuroscience Group | Nashville | Tennessee | 37203 | United States |
| The Innovative Clinical Research Center | Alexandria | Virginia | 22304 | United States |
| Swedish Headache Center | Seattle | Washington | 98104 | United States |
| FG002 | Sham TMS Device | Device which does not deliver TMS pulse |
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Treatment Phase |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active Transcranial Magnetic Stimulation (TMS) Device | Active Transcranial Magnetic Stimulation Device Treatment |
| BG001 | Sham TMS Device | Simulated Sham treatment without TMS |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Experiencing no Pain at Two Hours Post-treatment | Number of participants experiencing no pain at two hours post-treatment divided by total number of participants treated. For each treated aura episode during the migraine treatment phase, the subjects rated the pain intensity of their headache as none, mild, moderate or severe at baseline (before application of the study device) at 30 minutes, and at 1, 2, 24, and 48 hours posttreatement. | Full-analysis set: intention to treat population (201) adjusted for those participants who did not administer treatment during the study period | Posted | Number | percentage of participants | Two hours |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Have Symptoms of Nausea | Percentage of participants who have symptoms of nausea two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. | Posted | Number | percentage of participants | two hours post treatment |
|
| |||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Have Symptoms Phonophobia | Percentage of participants who have symptoms of phonophobia two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. | Posted | Number | Percentage of Participants | 2 hours post treatment |
|
| |||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Have Photophobia | Percentage of participants who have symptoms of photophobia two hours post treatment. For each treated aura episode, the subjects rated the severity of photophobia, nausea, and phonophobia as none, mild, moderate, or severe at baseline and recorded the presence or absence of vomiting at baseline (before application of the device) at 30 minutes, and at 1, 2, 24 and 48 hours posttreatment. | Posted | Number | Percentage of participants | 2 hours post treatment |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Active TMS Device - Treatment Related | Active Transcranial Magnetic Stimulation Device Treatment - Treatment related | 0 | 102 | 7 | 102 | ||
| EG001 | Sham TMS Device - Treatment Related | Simulated Sham treatment without TMS | 0 | 99 | 2 | 99 | ||
| EG002 | Active TMS - Not Treatment Related | Active Transcranial Magnetic Stimulation Device Treatment - Not treatment related | 1 | 102 | 12 | 102 | ||
| EG003 | Sham TMS Device - Not Treatment Related | Sham TMS Device - events that are not treatment related | 0 | 99 | 8 | 99 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| optic neuritis | Eye disorders | Non-systematic Assessment | One serious adverse event,optic neuritis,was reported in one subject who was randomized to the TMS group. The optic neuritis for Subject was not considered by the investigator and medical monitor to be related to the study treatment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Headache | Nervous system disorders |
| |||
| Migraine | Nervous system disorders |
| |||
| Sinusitis | Respiratory, thoracic and mediastinal disorders |
| |||
| aphasia | Nervous system disorders |
| |||
| Application site pain | General disorders |
| |||
| Bronchitis | Respiratory, thoracic and mediastinal disorders |
| |||
| Dizzines | Nervous system disorders |
| |||
| Gastric ulcer | General disorders |
| |||
| Influenza | Respiratory, thoracic and mediastinal disorders |
| |||
| Nausea | General disorders |
| |||
| Optic neuritis | Nervous system disorders |
| |||
| Palpitations | Nervous system disorders |
| |||
| Rash | General disorders |
| |||
| Vertigo | Nervous system disorders |
| |||
| Vomiting | General disorders |
| |||
| Tempromandibular joint syndrome | General disorders |
| |||
| Concussion | Nervous system disorders |
| |||
| Neck Pain | Nervous system disorders |
| |||
| Paresthesia | Nervous system disorders |
| |||
| Road traffic Accident | General disorders |
| |||
| Sleep disorder | General disorders |
| |||
| Tooth infection | Infections and infestations |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Cynthia Merrell | Neuralieve | 408-245-6400 | cmerrell@neuralieve.com |
| ID | Term |
|---|---|
| D020325 | Migraine with Aura |
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D050781 | Transcranial Magnetic Stimulation |
| ID | Term |
|---|---|
| D055909 | Magnetic Field Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|